Arsenic trioxide-induced apoptosis in TM4 Sertoli cells: The potential involvement of p21 expression and p53 phosphorylation

Toxicology

Volumn 285, Issue 3, 2011, Pages 142-151

  Kim, Yoon Jae ^a   Chung, Jin Yong ^a   Lee, Seung Gee ^a   Kim, Ji Young ^a   Park, Ji Eun ^a   Kim, Won Rok ^a   Joo, Bo Sun ^b   Han, Seong Ho ^a   Yoo, Ki Soo ^a   Yoo, Young Hyun ^a   Kim, Jong Min ^a  

^a Dong A University   (South Korea)

^b Good Moonhwa Hospital   (South Korea)

Author keywords

Apoptosis; Arsenic trioxide; P21; P53; ROS; Sertoli cells

Indexed keywords

ARSENIC TRIOXIDE; CASPASE 3; P21 ACTIVATED KINASE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SERINE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; GENOTOXICITY; MALE; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SERTOLI CELL;

ANIMALS; APOPTOSIS; ARSENICALS; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL LINE; CYTOCHROMES C; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; ONCOGENE PROTEIN P21(RAS); OXIDES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; SERTOLI CELLS; TUMOR SUPPRESSOR PROTEIN P53;

ANIMALIA;

EID: 79957800277     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.04.013     Document Type: Article

References (42)

1. Akay C., Gazitt Y. Arsenic trioxide selectively induces early and extensive apoptosis via the APO2/caspase-8 pathway engaging the mitochondrial pathway in myeloma cells with mutant p53. Cell Cycle 2003, 2:358-368.
2. Ando T., Kawabe T., Ohara H., Ducommun B., Itoh M., Okamoto T. Involvement of the interaction between p21 and proliferating cell nuclear antigen for the maintenance of G2/M arrest after DNA damage. J. Biol. Chem. 2001, 276:42971-42977.
3. Balaban R.S., Nemoto S., Finkel T. Mitochondria, oxidants, and aging. Cell 2005, 120:483-495.
4. Bálint E.E., Vousden K.H. Activation and activities of the p53 tumour suppressor protein. Br. J. Cancer 2001, 85:1813-1823.
5. Buttke T.M., Sandstrom P.A. Oxidative stress as a mediator of apoptosis. Immunol. Today 1994, 15:7-10.
6. Candé C., Cecconi F., Dessen P., Kroemer G. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death?. J. Cell. Sci. 2002, 115:4727-4734.
7. Chen J., Jackson P.K., Kirschner M.W., Dutta A. Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. Nature 1995, 374:386-388.
8. Chen M.J., Yang P.Y., Ye Y.Z., Hu D.N., Chen M.F. Arsenic trioxide induces apoptosis in uveal melanoma cells through the mitochondrial pathway. Am. J. Chin. Med. 2010, 38:1131-1142.
9. Chiou T.J., Chu S.T., Tzeng W.F., Huang Y.C., Liao C.J. Arsenic trioxide impairs spermatogenesis via reducing gene expression levels in testosterone synthesis pathway. Chem. Res. Toxicol. 2008, 21:1562-1569.
10. Cullen W.R., Reimer K.J. Arsenic speciation in the environment. Chem. Rev. 1989, 89:713-774.
11. Davison K., Cote S., Mader S., Miller W.H. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003, 17:931-940.
12. Douer D., Tallman M.S. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies. J. Clin. Oncol. 2005, 23:2396-2410.
13. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 2002, 1:639-649.
14. Gartenhaus R.B., Prachand S.N., Paniaqua M., Li Y., Gordon L.I. Arsenic trioxide cytotoxicity in steroid and chemotherapy-resistant myeloma cell lines: enhancement of apoptosis by manipulation of cellular redox state. Clin. Cancer Res. 2002, 8:566-572.
15. Hayashi T., Hideshima T., Akiyama M., Richardson P., Schlossman R.L., Chauhan D., Munshi N.C., Waxman S., Anderson K.C. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol. Cancer Ther. 2002, 1:851-860.
16. 3: an experience of 120 patients at a single institution. Int. J. Hematol. 1999, 70:248-260.
17. International Agency for Research on Cancer, 2004. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Some Drinking-Water Disinfectants and Contaminants, Including Arsenic, vol. 84. International Agency for Research on Cancer, Lyon.
18. Jegou B. The Sertoli-germ cell communication network in mammals. Int. Rev. Cytol. 1993, 147:25-96.
19. Kang Y.H., Yi M.J., Kim M.J., Park M.T., Bae S., Kang C.M., Cho C.K., Park I.C., Park M.J., Rhee C.H., Hong S.I., Chung H.Y., Lee Y.S., Lee S.J. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly (ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res. 2004, 64:8960-8967.
20. Kawai H., Wiederschain D., Yuan Z.M. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol. Cell. Biol. 2003, 23:4939-4947.
21. Kitamura K., Minami Y., Yamamoto K., Akao Y., Kiyoi H., Saito H., Naoe T. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis. Leukemia 2000, 14:1743-1750.
22. Lavin M.F., Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ. 2006, 13:941-950.
23. Li Y., Qu X., Qu J., Zhang Y., Liu J., Teng Y., Hu X., Hou K., Liu Y. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 2009, 284:208-215.
24. Liu J., Waalkes M.P. Liver is a target of arsenic carcinogenesis. Toxicol. Sci. 2008, 105:24-32.
25. Liu Q., Hilsenbeck S., Gazitt Y. Arsenic trioxide-induced apoptosis in myeloma cells: p53-dependent G1 or G2/M cell cycle arrest, activation of caspase-8 or caspase-9, and synergy with APO2/TRAIL. Blood 2003, 101:4078-4087.
26. McCafferty-Grad J., Bahlis N.J., Krett N., Aguilar T.M., Reis I., Lee K.P., Boise L.H. Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells. Mol. Cancer Ther. 2003, 2:1155-1164.
27. Miller W.H., Schipper H.M., Lee J.S., Singer J., Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002, 62:3893-3903.
28. Norberg E., Gogvadze V., Vakifahmetoglu H., Orrenius S., Zhivotovsky B. Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. Free Radic. Biol. Med. 2010, 48:791-797.
29. Ralph S.J. Arsenic-based antineoplastic drugs and their mechanisms of action. Met. Based Drugs 2008, 2008:1-13.
30. Scholz C., Richter A., Lehmann M., Schulze-Osthoff K., Dörken B., Daniel P.T. Arsenic trioxide induces regulated, death receptor-independent cell death through a Bcl-2-controlled pathway. Oncogene 2005, 24:7031-7042.
31. 3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997, 89:3354-3360.
32. Smith A.H., Hopenhayn-Rich C., Bates M.N., Goeden H.M., Hertz-Picciotto I., Duggan H.M., Wood R., Kosnett M.J., Smith M.T. Cancer risks from arsenic in drinking water. Environ. Health Perspect. 1992, 97:259-267.
33. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardshti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N. Engl. J. Med. 1998, 339:1241-1348.
34. Sumi D., Shinkai Y., Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol. Appl. Pharmacol. 2010, 244:385-392.
35. Suzuki A., Tsutomi Y., Akahane K., Araki T., Miura M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998, 17:931-939.
36. Taylor B.F., McNeely S.C., Miller H.L., Lehmann G.M., McCabe M.J., States J.C. p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21CIP1/WAF1. J. Pharmacol. Exp. Ther. 2006, 318:142-151.
37. Uslu R., Sanli U.A., Sezgin C., Karabulut B., Terzioglu E., Omay S.B., Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 2000, 6:4957-4964.
38. Yih L.H., Lee T.C. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res. 2000, 60:6346-6352.
39. Yoda A., Toyoshima K., Watanabe Y., Onishi N., Hazaka Y., Tsukuda Y., Tsukada J., Kondo T., Tanaka Y., Minami Y. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J. Biol. Chem. 2008, 283:18969-18979.
40. Yu B.P. Cellular defenses against damage from reactive oxygen species. Physiol. Rev. 1994, 74:139-162.
41. Zhang T.C., Cao E.H., Li J.F., Ma W., Qin J.F. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur. J. Cancer 1999, 35:1258-1263.
42. Zhao S., Zhang J., Zhang X., Dong X., Sun X. Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol. Biol. Rep. 2008, 35:421-429.